» Articles » PMID: 19264784

Unraveling Viral Interleukin-6 Binding to Gp130 and Activation of STAT-signaling Pathways Independently of the Interleukin-6 Receptor

Overview
Journal J Virol
Date 2009 Mar 7
PMID 19264784
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Human herpesvirus 8 encodes a viral version of interleukin-6 (vIL-6) which shows 25% sequence homology with human IL-6. In contrast to human IL-6, which first binds to the IL-6 receptor (IL-6R) and only subsequently associates with the signal transducing receptor subunit gp130, vIL-6 has been shown to directly bind to gp130 without the need of IL-6R. As a functional consequence, vIL-6 can activate far more target cells in the body since all cells express gp130, but only cells such as hepatocytes and some leukocytes express IL-6R. We sought to understand which amino acid sequences within the vIL-6 protein were responsible for its ability to bind and activate gp130 independent of IL-6R. As a first approach, we constructed chimeric IL-6 proteins in which all known gp130 interacting sites (sites II and III) were sequentially transferred from vIL-6 into the human IL-6 protein. To our surprise, human IL-6 carrying all gp130 interacting sites from vIL-6 did not show IL-6R-independent gp130 activation. Even more surprisingly, the loop between helix B and C of vIL-6, clearly shown in the crystal structure not to be in contact with gp130, is indispensable for direct binding to and activation of gp130. This points to an IL-6R induced change of site III conformation in human IL-6, which is already preformed in vIL-6. These data indicate a novel activation mechanism of human IL-6 by the IL-6R that will be important for the construction of novel hyperactive cytokine variants.

Citing Articles

Engineering synthetic signaling receptors to enable erythropoietin-free erythropoiesis.

Shah A, Majeti K, Ekman F, Selvaraj S, Sharma D, Sinha R Nat Commun. 2025; 16(1):1140.

PMID: 39880867 PMC: 11779867. DOI: 10.1038/s41467-025-56239-5.


The Role of vIL-6 in KSHV-Mediated Immune Evasion and Tumorigenesis.

Komaki S, Inagaki T, Kumar A, Izumiya Y Viruses. 2025; 16(12.

PMID: 39772207 PMC: 11680145. DOI: 10.3390/v16121900.


Interleukin-11 receptor is an alternative α-receptor for interleukin-6 and the chimeric cytokine IC7.

Weitz H, Ettich J, Rafii P, Wittich C, Schultz L, Frank N FEBS J. 2024; 292(3):523-536.

PMID: 39473075 PMC: 11796321. DOI: 10.1111/febs.17309.


Potential Application of Plant-Derived Compounds in Multiple Sclerosis Management.

Woodfin S, Hall S, Ramerth A, Chapple B, Fausnacht D, Moore W Nutrients. 2024; 16(17).

PMID: 39275311 PMC: 11397714. DOI: 10.3390/nu16172996.


5-AZA Upregulates SOCS3 and PTPN6/SHP1, Inhibiting STAT3 and Potentiating the Effects of AG490 against Primary Effusion Lymphoma Cells.

Di Crosta M, Arena A, Benedetti R, Gilardini Montani M, Cirone M Curr Issues Mol Biol. 2024; 46(3):2468-2479.

PMID: 38534772 PMC: 10968859. DOI: 10.3390/cimb46030156.


References
1.
Nador R, Cesarman E, Chadburn A, Dawson D, Ansari M, Sald J . Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996; 88(2):645-56. View

2.
Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N . Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2000; 268(1):160-7. DOI: 10.1046/j.1432-1327.2001.01867.x. View

3.
Soulier J, GROLLET L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P . Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995; 86(4):1276-80. View

4.
Nicholls A, Sharp K, Honig B . Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins. 1991; 11(4):281-96. DOI: 10.1002/prot.340110407. View

5.
Dela Cruz C, Lee Y, Viswanathan S, El-Guindy A, Gerlach J, Nikiforow S . N-linked glycosylation is required for optimal function of Kaposi's sarcoma herpesvirus-encoded, but not cellular, interleukin 6. J Exp Med. 2004; 199(4):503-14. PMC: 2211829. DOI: 10.1084/jem.20031205. View